All In Biotech

Drug Trial Radar · NCT02953340

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER)

Last checked: Nov 20, 2026Latest source record: Mar 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 237 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

237

Actual

Start

May 10, 2017

Primary completion

Jun 8, 2018

Study completion May 6, 2019

Sponsor

Lead sponsor
Spectrum Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Nov 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia (DSN).

Conditions

  • Neutropenia
  • Breast Cancer

Interventions

  • SPI-2012Drug

    Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle

  • PegfilgrastimDrug

    Subcutaneous injection administered on Day 2 of each cycle.

  • DocetaxelDrug

    75mg/m\^2 IV infusion administered on Day 1 of each cycle

  • CyclophosphamideDrug

    600mg/m\^2 IV infusion administered on Day 1 of each cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of Severe Neutropenia (DSN) in Cycle 1Time frame: Day 1 and daily on Days 4-15 in Cycle 1 (each cycle = 21 days)

Locations

74 sites in 6 countries. Site status is shown where the registry gives one.

  • ACRC/ Arizona Clinical Research Center Inc.

    Tucson, Arizona

  • Yuma Regional Cancer Center

    Yuma, Arizona

  • Genesis Cancer Center

    Hot Springs, Arkansas

  • NEA Baptist Clinic | Fowler Family Center for Cancer Care

    Jonesboro, Arkansas

  • Pacific Cancer Medical Center, Inc.

    Anaheim, California

  • Compassionate Care Research Group, Inc.

    Fountain Valley, California

  • California Cancer Associates for Research and Excellence Inc.

    Fresno, California

  • Pacific Shores Medical Group

    Long Beach, California

  • Los Angeles Hematology Oncology Medical Group

    Los Angeles, California

  • Desert Regional Medical Center

    Palm Springs, California

  • Emad Ibrahim, MD, INC.

    Redlands, California

  • Innovative Clinical Research Institute/ The Oncology Institute of Hope and Innovation

    Whittier, California

  • Denver Health & Hospital Authority

    Denver, Colorado

  • Pasco Pinellas Cancer Center

    Holiday, Florida

  • Lakes Research, LLC

    Miami Lakes, Florida

  • Mid-Florida Hematology and Oncology Centers

    Orange City, Florida

  • Millennium Oncology

    Pembroke Pines, Florida

  • BRCR Medical Center Inc

    Plantation, Florida

  • Pinellas Hematology and Oncology

    St. Petersburg, Florida

  • Bond & Steele Clinic, PA.

    Winter Haven, Florida

  • John B. Amos Cancer Center

    Columbus, Georgia

  • Cancer Center of Middle Georgia

    Dublin, Georgia

  • Dwight D. Eisenhower Army Medical Center

    Fort Gordon, Georgia

  • Saint Alphonsus Regional Medical Center

    Boise, Idaho

  • Oncology Specialists, SC

    Park Ridge, Illinois

  • FPN Oncology and Hematology Specialists

    Indianapolis, Indiana

  • Commonwealth Hematology-Oncology, PSC

    Danville, Kentucky

  • Pontchartrain Cancer Center

    Covington, Louisiana

  • Quest Research Institute

    Royal Oak, Michigan

  • Coborn Cancer Center

    Saint Cloud, Minnesota

  • Hattiesburg Clinic Hematology/Oncology

    Hattiesburg, Mississippi

  • Freeman Health Systems

    Joplin, Missouri

  • St. Vincent Frontier Cancer Center

    Billings, Montana

  • CHI Health St Francis, St Francis Cancer Treatment Center

    Grand Island, Nebraska

  • Waverly Hematology Oncology

    Cary, North Carolina

  • Gaston Hematology & Oncology Associates, PC

    Gastonia, North Carolina

  • Aultman Hospital

    Canton, Ohio

  • The Christ Hospital Cancer Center

    Cincinnati, Ohio

  • St. Elizabeth Youngstown Hospital JACBCC/Oncology/ Mercy Health Youngstown LLC

    Youngstown, Ohio

  • Carolina Blood and Cancer Care Associates

    Rock Hill, South Carolina

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.